Cover Image
市場調查報告書

Isarna Therapeutics GmbH的產品平台分析

Isarna Therapeutics GmbH - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 295948
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Isarna Therapeutics GmbH的產品平台分析 Isarna Therapeutics GmbH - Product Pipeline Review - 2015
出版日期: 2015年03月31日 內容資訊: 英文 35 Pages
簡介

Isarna Therapeutics GmbH是總公司設立於德國的生物科技企業,開發治療癌症,眼科疾病,纖維化疾病等所用的選擇性TGF-βs抑制劑。此外也利用反義技術來開發治療惡化性朣瘤所用的治療藥。

本報告提供Isarna Therapeutics GmbH 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Isarna Therapeutics GmbH 基本資料

  • Isarna Therapeutics GmbH 概要
  • 主要資訊
  • 企業資料

Isarna Therapeutics GmbH :R&D概要

  • 主要的治療範圍

Isarna Therapeutics GmbH :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Isarna Therapeutics GmbH :開發中產品概況

  • 初期階段的開發中產品
    • IND/CTA登記前的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Isarna Therapeutics GmbH :藥物簡介

  • ISTH-0036
  • Antisense Oligonucleotide to Inhibit TGF-beta1 for Fibrosis
  • Antisense Oligonucleotide to Inhibit TGF-beta1 for Ophthalmology
  • Antisense Oligonucleotide to Inhibit TGF-beta2 for Fibrosis
  • Antisense Oligonucleotide to Inhibit TGF-beta2 for Ophthalmology
  • ASPH-0047
  • ASPH-1047
  • ASPH-1106
  • Antisense Oligonucleotide to Inhibit TGF-beta + Chemotherapy for Cancer
  • Antisense Oligonucleotide to Inhibit TGF-beta + Vaccine for Cancer
  • Antisense Oligonucleotides to Inhibit TGF-beta3 for Cancer

Isarna Therapeutics GmbH :開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Isarna Therapeutics GmbH :開發暫停中的計劃

Isarna Therapeutics GmbH :開發中止的開發中產品

  • 開發中止的開發中產品簡介

Isarna Therapeutics GmbH :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06873CDB

Summary

Global Markets Direct's, 'Isarna Therapeutics GmbH - Product Pipeline Review - 2015', provides an overview of the Isarna Therapeutics GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Isarna Therapeutics GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Isarna Therapeutics GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Isarna Therapeutics GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Isarna Therapeutics GmbH's pipeline products

Reasons to buy

  • Evaluate Isarna Therapeutics GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Isarna Therapeutics GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Isarna Therapeutics GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Isarna Therapeutics GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Isarna Therapeutics GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Isarna Therapeutics GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Isarna Therapeutics GmbH Snapshot
    • Isarna Therapeutics GmbH Overview
    • Key Information
    • Key Facts
  • Isarna Therapeutics GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Isarna Therapeutics GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Isarna Therapeutics GmbH - Pipeline Products Glance
    • Isarna Therapeutics GmbH - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Isarna Therapeutics GmbH - Drug Profiles
    • ISTH-0036
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit TGF-beta1 for Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit TGF-beta1 for Ophthalmology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit TGF-beta2 for Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit TGF-beta2 for Ophthalmology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASPH-0047
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASPH-1047
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASPH-1106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit TGF-beta + Chemotherapy for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit TGF-beta + Vaccine for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotides to Inhibit TGF-beta3 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Isarna Therapeutics GmbH - Pipeline Analysis
    • Isarna Therapeutics GmbH - Pipeline Products by Target
    • Isarna Therapeutics GmbH - Pipeline Products by Molecule Type
    • Isarna Therapeutics GmbH - Pipeline Products by Mechanism of Action
  • Isarna Therapeutics GmbH - Dormant Projects
  • Isarna Therapeutics GmbH - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • trabedersen
  • Isarna Therapeutics GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Isarna Therapeutics GmbH, Key Information
  • Isarna Therapeutics GmbH, Key Facts
  • Isarna Therapeutics GmbH - Pipeline by Indication, 2015
  • Isarna Therapeutics GmbH - Pipeline by Stage of Development, 2015
  • Isarna Therapeutics GmbH - Monotherapy Products in Pipeline, 2015
  • Isarna Therapeutics GmbH - Combination Treatment Modalities in Pipeline, 2015
  • Isarna Therapeutics GmbH - IND/CTA Filed, 2015
  • Isarna Therapeutics GmbH - Preclinical, 2015
  • Isarna Therapeutics GmbH - Discovery, 2015
  • Isarna Therapeutics GmbH - Pipeline by Target, 2015
  • Isarna Therapeutics GmbH - Pipeline by Molecule Type, 2015
  • Isarna Therapeutics GmbH - Pipeline Products by Mechanism of Action, 2015
  • Isarna Therapeutics GmbH - Dormant Developmental Projects,2015
  • Isarna Therapeutics GmbH - Discontinued Pipeline Products, 2015

List of Figures

  • Isarna Therapeutics GmbH - Pipeline by Top 10 Indication, 2015
  • Isarna Therapeutics GmbH - Pipeline by Stage of Development, 2015
  • Isarna Therapeutics GmbH - Monotherapy Products in Pipeline, 2015
  • Isarna Therapeutics GmbH - Pipeline by Top 10 Target, 2015
  • Isarna Therapeutics GmbH - Pipeline by Top 10 Molecule Type, 2015
  • Isarna Therapeutics GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top